TY - JOUR
T1 - Anti-VEGF Bevacizumab (Avastin®) for Radiation Optic Neuropathy
AU - Finger, Paul T.
N1 - Funding Information:
This study was supported in part by a Grant from John and Myrna Daniels, Toronto, Ontario, Canada, and The EyeCare Foundation, New York, New York. The author indicates no financial conflict of interest. The author was involved in collection, management, analysis and interpretation of data, and preparation of the data and revision including references; involved in collection of data; and involved in management, statistical analysis and interpretation of the data, and preparation of the manuscript.
PY - 2007/2
Y1 - 2007/2
N2 - Purpose: To evaluate intravitreal bevacizumab treatment for radiation optic neuropathy (RON). Design: Interventional case report. Methods: At The New York Eye Cancer Center, a patient symptomatic of decreased vision because of RON was treated with intravitreal bevacizumab (1.25 mg). Main outcome measures included visual acuity, appearance of the optic nerve, fundus photography, angiography, and optical coherence tomography/scanning laser ophthalmoscopy (OCT/SLO). Results: Within one week, her vision improved from 20/32 to 20/20 with a reduction in optic disk hemorrhage. At six weeks, evidence of both decreased hemorrhage and optic disk edema was documented by photography, angiography, and OCT/SLO. At the three and five-month follow-up visits, the hemorrhages resolved, and her disk margins were sharp. There were no ocular or systemic side effects. Conclusions: Intravitreal bevacizumab was tolerated, improved vision, and reduced hemorrhage as well as optic disk edema (angiographic leakage). Anti-VEGF therapy (e.g. bevacizumab) should be investigated for both ocular and nonocular radiation neuropathy.
AB - Purpose: To evaluate intravitreal bevacizumab treatment for radiation optic neuropathy (RON). Design: Interventional case report. Methods: At The New York Eye Cancer Center, a patient symptomatic of decreased vision because of RON was treated with intravitreal bevacizumab (1.25 mg). Main outcome measures included visual acuity, appearance of the optic nerve, fundus photography, angiography, and optical coherence tomography/scanning laser ophthalmoscopy (OCT/SLO). Results: Within one week, her vision improved from 20/32 to 20/20 with a reduction in optic disk hemorrhage. At six weeks, evidence of both decreased hemorrhage and optic disk edema was documented by photography, angiography, and OCT/SLO. At the three and five-month follow-up visits, the hemorrhages resolved, and her disk margins were sharp. There were no ocular or systemic side effects. Conclusions: Intravitreal bevacizumab was tolerated, improved vision, and reduced hemorrhage as well as optic disk edema (angiographic leakage). Anti-VEGF therapy (e.g. bevacizumab) should be investigated for both ocular and nonocular radiation neuropathy.
UR - https://www.scopus.com/pages/publications/33846362539
U2 - 10.1016/j.ajo.2006.09.014
DO - 10.1016/j.ajo.2006.09.014
M3 - Article
C2 - 17258524
AN - SCOPUS:33846362539
SN - 0002-9394
VL - 143
SP - 335
EP - 338
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 2
ER -